What's in a Name: When Exposure Becomes Infection
Summary
How much virus does it take to make you sick? The answer is more complicated—and more interesting—than you might think.
Every infection begins with an encounter between a pathogen and a host. But exposure doesn't always lead to infection, and the amount of virus you're exposed to is only part of the story.
In this episode of Infectious Dose, we're exploring the science behind the podcast's name. What exactly is an infectious dose? How do scientists measure it? Why can two people encounter the same virus and have completely different outcomes? And does being exposed to more virus mean you'll get sicker?
From laboratory experiments and dose-response curves to the real-world transmission of viruses like influenza, norovirus, and measles, we'll explore how infectious dose shapes our understanding of infection, transmission, and prevention, and why there's no single magic number that determines whether someone gets sick.
Listen here or scroll down to read full episode.
Full Episode
Picture two people spending an afternoon in the same room. Someone nearby has influenza. They talk, laugh, and breathe the same shared air. A few days later, one person is sick. The other feels perfectly fine.
Why? Maybe they didn't inhale the same amount of infectious virus. Maybe the virus landed in different parts of their airways. Maybe one had stronger protection from a previous infection or vaccination. Or maybe chance played a role in whether the virus managed to establish itself.
We often talk about exposure as though it were a switch. You were exposed, so now you either have the infection or you don't. But there's an entire biological story between encountering a virus and becoming infected.
How much infectious virus has to reach you? How much survives the trip? How many particles actually reach cells they can infect?
These are questions at the heart of virology and epidemiology. They're also the reason I called this podcast Infectious Dose.
So today, we're going to explore the science behind the name. What infectious dose really means, how scientists measure it, and why the numbers aren't always as straightforward as they seem.
This is What's in a Name? When Exposure Becomes Infection.
Defining the dose
Let's start with a distinction that sounds small but changes everything: exposure is not the same thing as infection. Said another way, being exposed to a pathogen is not the same thing as being infected by it.
Let me explain. An exposure dose is the amount of a pathogen someone encounters. But not everything encountered reaches the place where an infection could begin. Some virus-containing particles never enter the body. Some are trapped or cleared. Some contain damaged or noninfectious virus. The amount that actually reaches a susceptible site on your body is closer to what researchers mean by a delivered dose, although studies define and estimate these quantities differently.
Think of it like standing outside in a rainstorm. There's a certain amount of rain falling around you, but that doesn't tell us how much water actually lands on your skin. Some misses you entirely. Some hits your umbrella or your jacket. And even the water that reaches you doesn't necessarily soak through. Exposure to a virus works a little like that. What you're surrounded by isn't necessarily what gets through.
An infectious dose is a quantity of infectious virus associated with establishing infection in a specified host under specified conditions. The host, the virus strain, the route of exposure, and even the method used to measure the virus all influence the answer.
You may have seen the term ID-fifty (ID=Infectious Dose), written ID₅₀. It means the dose estimated to infect fifty percent of a defined population under the conditions of a specific study. It doesn't mean half a virus, and it doesn't mean everyone below that dose is safe while everyone above it is infected.
Think of a dose-response curve. At very low doses, the probability of infection may be small. As the dose increases, that probability generally rises. ID-fifty marks the point where the modeled or measured probability reaches fifty percent. It isn't a universal line in the sand.
And then there's LD-fifty (LD stands for Lethal dose), that's the dose that causes death in fifty percent of the experimental group. Infection and death are very different outcomes. A virus can establish infection without causing symptoms, and infection can cause symptoms without causing severe disease or death.
You may hear someone say, 'It only takes one virus to infect you.' Under some theoretical models, a single viable infectious unit has a nonzero probability of initiating infection. But that doesn't mean that a single physical particle will reliably infect a person. One particle might be damaged. It might never reach a susceptible cell. It might be stopped by host defenses. And a laboratory infectious unit isn't necessarily one virion, which is what we call a virus particle.
So when somebody gives you a precise infectious dose number, the first questions should be: for which virus, which host, which exposure route, which endpoint, and measured in what units?
The obstacle course between exposure and infection
Let's follow a hypothetical respiratory virus.
A person with an infection breathes out particles of different sizes. Some contain infectious virus; others may contain viral genetic material but no virus capable of replicating. Those particles enter the air, where dilution, ventilation, filtration, humidity, time, and other conditions influence infectivity and what happens next.
Another person inhales. But inhaling virus-containing air isn't the end of the story. Different particles can deposit in different regions of the respiratory tract. The nose and upper airway have mucus and moving cilia that help clear inhaled material. Other defenses act quickly, including antiviral signaling and immune cells.
For infection to take hold, at least some infectious virus must reach cells it can enter. Cells it can enter are cells that display the right molecular features, like a protein it can bind to and use to get inside known as a receptor...and then the internal environment of the cell must support replication. Then the virus has to produce new infectious particles and spread sufficiently to establish what's called productive infection.
This is why the phrases 'virus in the air' or 'infectious dose received' are not interchangeable. The amount emitted by a source, the amount suspended in air, the amount inhaled, the amount deposited, and the amount that successfully initiates productive infection are related but not synonymous.
And another related idea here is something called the transmission bottleneck. This refers to the idea that even though an infected person may carry billions of viral particles with diverse genetic mutations, the physical and biological barriers of transmission and infection act as filters, seriously reducing the genetic diversity in the newly infected individual. Researchers can study viral genetic sequences to estimate how many distinct viral lineages successfully established themselves in the next host.
Imagine a crowd of thousands trying to get through a series of narrow doorways. Most never make it through. And the handful that do may not represent all the different kinds of people who started out in that crowd. Something similar can happen during virus transmission. A huge, genetically diverse population of viruses in one person can give rise to an infection founded by a much smaller and less diverse group in the next.
So this reinforces our bottom line: the amount of virus someone encounters isn't necessarily the amount that successfully establishes an infection. Along the way, viruses face physical barriers, immune defenses, and a certain amount of biological chance. The transmission bottleneck gives scientists a window into just how selective that process can be. It's another reminder that infection isn't about how much virus is present. It's about how much gets through and successfully begins to replicate.
Counting viruses in the laboratory
Virologists spend a lot of time counting things that aren't quite as straightforward to count as they sound.
One approach to quantify viruses is to detect viral genetic material using PCR or a related method. These tests can be extremely sensitive. But viral RNA or DNA isn't the same as finding infectious virus. Genetic material may remain after infectivity has been lost. And a copy of a genome isn't the same as a virus capable of establishing infection.
Another approach is the plaque assay, which measures infectious activity in cultured cells. In a plaque assay, researchers dilute a virus sample and apply it to susceptible cells. Under suitable conditions, an infectious event can produce a localized area of cell damage that we call a plaque. The result is expressed in plaque-forming units, or PFU.
That sounds like counting individual virions, but it isn't. A plaque-forming unit is an operational measure: one plaque may originate from one infectious particle or, in some circumstances, an aggregate. The result depends on the cells and assay conditions.
Another method is TCID-fifty, a laboratory estimate of the amount of virus needed to produce a detectable infection-related effect in fifty percent of inoculated cell cultures under specific conditions. Like plaque-forming units, TCID-fifty measures infectious activity in a specific laboratory system. It doesn't tell us directly how many individual virus particles were present, and it isn't the same as the ID-fifty for a human being.
And fifty percent of cell cultures showing infection isn’t the same thing as fifty percent of people becoming infected.
Also, units can’t be casually swapped. A study reporting thousands of genomic copies, another reporting PFU, and another reporting TCID-fifty aren’t necessarily describing equivalent amounts of infectious virus. Conversions depend on the virus, the preparation, the assay, and the assumptions.
The important thing to remember is that counting viral genetic material, measuring infectious activity in cells, and determining how much virus infects a person are three different things. They're related, but they aren't interchangeable. And that's why two studies can report very different-looking numbers without necessarily disagreeing about the biology.
How, then, do scientists estimate the infectious dose in an actual host? One approach is to expose experimental hosts to different known doses, monitor whether infection becomes established, and use the results to build a dose-response curve.
And yes, some of these experiments have involved humans. They're called human challenge studies, and they involve deliberately exposing consenting volunteers to a pathogen under carefully controlled conditions.
Now, deliberately infecting people for research raises some obvious ethical questions. But human challenge studies have been conducted for decades, including with viruses like influenza, rhinovirus, and norovirus.
And it's important to acknowledge that the history of human infection research includes serious ethical abuses. In Guatemala in the 1940s, U.S. government researchers deliberately exposed vulnerable people to sexually transmitted infections without their informed consent.
And while the infamous Tuskegee syphilis study did not involve deliberately infecting participants, researchers deceived Black men who already had syphilis and withheld effective treatment, even after penicillin became available.
These are different kinds of ethical violations, but both are reminders of why informed consent, independent oversight, and protection of research participants are so essential.
Today, these studies require rigorous ethical review, a strong scientific justification, careful participant selection, and measures to minimize risk. They're not appropriate for every pathogen, and researchers have to consider whether the same questions could be answered using less risky methods.
Increasingly, scientists also use mathematical models, observational data, and experimental systems to estimate infectious dose without deliberately infecting people. But those approaches have limitations. Models depend on the quality of the data and assumptions behind them, and what happens in a laboratory or an animal model doesn't always translate neatly to human infection.
That's part of what makes infectious dose so difficult to pin down. The most direct way to study it in humans isn't always ethically acceptable, and the alternatives don't always give us a definitive answer.
And if determining infectious dose under controlled conditions is complicated, figuring out how much virus someone encountered during an actual outbreak is even harder.
In the real world, the original dose is usually unknown. Epidemiologists may know who became infected after an event, how long people shared an environment, and sometimes how much virus was measured in air or on surfaces. But reconstructing the dose delivered to each person's susceptible tissue is difficult. Models help bridge that gap; models also introduce assumptions.
So we've established two things. First, encountering a virus isn't the same as becoming infected. And second, even measuring how much infectious virus is present is more complicated than it sounds. Now we can get to the really interesting question: how does the amount of virus change the probability of infection?
The probability curve
And that brings us to the most important idea in this episode: for many viruses, infectious dose is best understood as a relationship between dose and the probability of infection, not a magical minimum number.
One simplified model assumes that each infectious unit has an independent chance of establishing infection. Under those assumptions, the probability that at least one unit succeeds rises as the number of units increases. Researchers sometimes call this a single-hit framework.
Think about rolling a die. If you need to roll a six to win, every roll gives you a one-in-six chance. And that chance doesn't change, no matter how many times you roll. But if you roll the die ten times, your overall chance of getting at least one six is much higher than if you roll it just once.
That's the basic idea behind this model. Each infectious unit has some probability of successfully establishing infection, and increasing the number of opportunities increases the probability that at least one succeeds.
Of course, real viruses and real immune systems are much more complicated than dice. But the analogy helps explain why a single infectious unit might theoretically establish infection, while larger doses generally make infection more likely.
But viruses may aggregate. Some hosts may already have immunity. Different people may vary in susceptibility. And the probability that a measured unit is actually infectious in the relevant tissue may be uncertain. Keep in mind, though, that this is a mathematical framework. It helps scientists describe infection probabilities; it doesn't prove that every virus particle acts independently or has the same chance of establishing an infection in a real person. More complex dose-response models account for some of this variability, but even those models have limitations.
Norovirus is an instructive example of this. It's often described as having an extremely low infectious dose. That captures its efficient transmission, but the exact number depends heavily on the study and the model. In one controlled Norwalk virus challenge study, researchers estimated an ID-fifty using reverse-transcription PCR units, with estimates differing according to which susceptible participants were included. The authors also reported genomic equivalents, which are a different measurement, not a simple count of infectious virions.
Other investigators reanalyzed norovirus challenge and outbreak data and showed how assumptions about immunity, susceptibility, and viral diversity change estimated risks. A recent meta-analysis likewise compared multiple dose-response models and found that the available evidence remains sensitive to the way host immunity and viral genogroups are represented.
So when you hear that 'just a handful of norovirus particles can infect you,' treat that as a shorthand for high infectivity, not as a universally established particle-count threshold.
There's also a crucial difference between being infected and becoming ill. In norovirus studies, some infected participants develop gastroenteritis while others don't. A dose-response curve for infection is not necessarily the same curve as one for symptoms.
And this leads to another tempting—but risky—assumption: if a bigger dose makes infection more likely, does it also make illness more severe?
Sometimes experimental studies do find that a larger inoculum, meaning a greater amount of infectious virus administered, is associated with certain features of illness, such as symptoms appearing sooner or increased viral shedding. Now, a secondary analysis of a norovirus challenge study, for example, found faster onset with increasing inoculum and a possible association with symptom severity, while some effects were inconclusive. But we can't turn that into a rule that more virus always means more severe disease.
Once infection is established, virus replication, immune responses, the tissues involved, prior immunity, age, and other host factors all shape the outcome. And in observational studies, it's especially difficult to separate initial exposure dose from what happens after the virus begins replicating.
A bigger dose generally means greater infection risk under otherwise similar conditions. But a bigger dose doesn't automatically mean a worse clinical outcome.
So far, we've talked about the principles. But what does all of this look like when we compare actual viruses?
Three viruses, three different lessons
Let’s do it.
First, norovirus. It spreads efficiently through fecal-oral routes, including contaminated food, water, hands, and surfaces. Vomiting events can disperse material into the surrounding environment. Environmental stability, opportunities for contamination, the amount of virus shed, and differences in host susceptibility all play a role here. For some norovirus strains, a person's secretor status—related to expression of certain histo-blood group antigens—can substantially change susceptibility. Two people may encounter the same contamination and face very different risks.
In simpler terms, our genes influence which molecular structures appear on the surfaces of our cells. Certain noroviruses use those structures when infecting us. So a person's genetics can make it easier or harder for a specific norovirus strain to establish infection. It's one reason two people can encounter the same virus and have very different outcomes.
Now for influenza. Here, exposure route can be revealing. In a landmark 1966 human challenge experiment, Alford and colleagues exposed volunteers to small-particle aerosols containing influenza virus. They found that infection could occur at relatively low aerosol doses in their study population. Later reviews assembled studies using different inoculation methods and showed why comparing aerosol delivery with nasal instillation requires caution. The results are not a universal infectious dose for all influenza viruses, all people, or all respiratory exposures.
Imagine trying to compare an amount placed directly into the nose with an amount carried by inhaled particles that deposit across the respiratory tract. Even if the laboratory reports both in TCID-fifty, the biological circumstances are different.
Finally, let's look at measles. Measles is famously transmissible in susceptible populations. But its transmissibility emerges from several combined features: like how and when infectious virus is emitted, how exposure occurs, how susceptible contacts are, how people mix, and how efficiently infection becomes established. Population immunity is central here.
This is why the basic reproduction number, or R-naught, cannot be converted into an infectious dose. R-naught describes the average number of secondary infections generated by a typical infectious case in a fully susceptible population under specific conditions. It's not a laboratory measurement of the number of virions needed to infect a cell or a person.
Think of it this way: R-naught tells us something about how widely an infection can spread through a susceptible population. Infectious dose tells us something about the amount of virus associated with establishing infection in an individual. One is about the pattern of spread between people. The other is about what happens during an individual encounter. You can't just calculate one from the other
Norovirus reminds us that host biology is important. Influenza reminds us that route is important. Measles reminds us that transmission is a population-level phenomenon, not just a number of particles.
What dose tells us about prevention
All of this might sound abstract, but it has practical implications.
If the chance of infection rises with the amount of infectious virus that reaches a susceptible site, then reducing exposure can reduce risk even when you can't guarantee that exposure is zero.
For respiratory viruses transmitted through inhalation, cleaner indoor air can reduce the concentration of infectious particles people breathe. Ventilation dilutes contaminated indoor air; filtration removes particles; a well-fitting respirator reduces the amount inhaled by the wearer. These measures act at different points along the pathway from emission to inhalation.
For pathogens transmitted through contaminated hands, food, water, or surfaces, prevention targets those pathways instead. Soap-and-water handwashing is really important in norovirus prevention. As are food safety and careful environmental cleaning including using disinfectants with demonstrated effectiveness against norovirus and following their instructions for use.
Vaccination works differently, it changes the host's immune readiness. Depending on the vaccine and pathogen, that can reduce severe disease and risk of death.
One caution here: lowering exposure isn't a promise that the remaining dose is harmless. Because infection can be probabilistic, a small exposure may still establish infection. And we generally can't identify a universal 'safe' exposure threshold for an individual.
Still, this is why we emphasize layered prevention. Different measures can reduce the opportunities for virus to reach a susceptible host or reduce the chance that exposure produces infection.
What remains uncertain
We've learned a lot about infectious dose, but there are some stubborn gaps.
For many human viruses, we don't have reliable dose-response data from ethically acceptable human experiments. Animal models may help, but their results don't transfer automatically to people. And in cell cultures we can measure infectivity only in specific cells, not in a whole host.
Real-world exposure is rarely measured directly. A person might encounter repeated small exposures rather than one neat dose. People differ in immune history, age, genetics, and susceptibility. Virus strains differ. Even the definition of infection can vary among studies and things like virus shedding, a positive molecular test, seroconversion, or symptoms, are not equivalent endpoints.
And dose-response models can be precise-looking while still being uncertain. A calculated ID-fifty may depend on which participants were included, how many dose levels were tested, and what mathematical model was chosen.
The strongest answer to 'How much virus does it take?' is often not a single number. It's a careful explanation of what was measured, in whom, by which route, and with how much uncertainty.
Closing — the name behind the science
Every infection begins with an encounter. But a virus has to survive a series of obstacles, reach the right cells, and establish replication in a host whose defenses and history play a role.
Infectious dose gives us a way to think about that encounter. It reminds us that transmission depends on how much infectious virus reaches someone, where it goes, and the probability that infection takes hold.
And it reminds us to be cautious with numbers that sound more certain than the underlying evidence makes them.
That's why I called this podcast Infectious Dose. Because behind every outbreak, every transmission chain, and every infection is a fascinating intersection of virology, human biology, and chance.
If you enjoyed this episode, consider sharing it with someone else who might find this story interesting. You can also help support Infectious Dose by following or subscribing wherever you listen. Those small things really do help new listeners find the show.
Annotated Citations
Each citation is annotated to explain how the source connects to the episode and to help listeners who want to explore the science in greater depth.
Accessing the literature: Whenever possible, I've linked directly to free full-text articles and books that are legally available online. For subscription-only journal articles, many researchers are happy to share a personal copy of their work if you contact the corresponding author. For books, I've included links to free online lending copies or library catalogs when available. If a title isn't freely available online, I've linked WorldCat to locate it at a nearby library or you can ask your local library about interlibrary loans.
Understanding infectious dose
1. Yezli S, Otter JA. 2011. Minimum infective dose of the major human respiratory and enteric viruses transmitted through food and the environment. Food and Environmental Virology.
→ A foundational review of infectious dose across respiratory and enteric viruses. It explores why estimates vary depending on the virus, exposure route, host susceptibility, and experimental methods. This provides important background for the episode's central argument: infectious dose is not a universal number that applies equally to every person or exposure.
🔒Subscription required: https://doi.org/10.1007/s12560-011-9056-7
2. Schmidt PJ. 2015. Norovirus dose-response: are currently available data informative enough to determine how susceptible humans are to infection from a single virus? Risk Analysis.
→ A critical examination of norovirus dose-response modeling and the uncertainty surrounding estimates of infection probability at very low doses. Particularly relevant to the discussion of single-hit models, assumptions about independent infectious units, and why mathematical estimates should not be mistaken for experimentally established thresholds.
🔒Subscription required: https://doi.org/10.1111/risa.12323
3. Liu Z, Kitajima M, Katayama H. 2026. Revisiting norovirus dose-response models: A meta-analysis and multi-model comparison for waterborne risk assessment. Water Research.
→ A recent meta-analysis comparing mathematical models used to estimate norovirus infection risk. The authors evaluated 408 publications and extracted 37 dose-response datasets, examining how model selection, host immunity, and viral genogroup influence estimates. This supports the episode's explanation of why different studies can produce different infectious-dose estimates without contradicting one another.
🔒Subscription required:
Transmission bottlenecks and host susceptibility
4. McCrone JT, et al. 2018. Stochastic processes constrain the within and between host evolution of influenza virus. eLife.
→ A study of influenza virus genetic diversity and transmission bottlenecks. The researchers found evidence that only a limited portion of the viral diversity present in one host is typically represented in the next. It helps illustrate how transmission and infection can act as biological filters, although genetic bottleneck estimates are not direct measurements of infectious dose.
🌐 Open access: https://elifesciences.org/articles/35962
5. Teunis PFM, et al. 2020. Noroviruses are highly infectious but there is strong variation in host susceptibility and virus pathogenicity. Epidemics.
→ An analysis demonstrating that norovirus infection risk varies considerably with host susceptibility and viral characteristics. This supports the episode's discussion of why two people encountering similar amounts of virus may have different outcomes, and why infectious-dose estimates must account for biological variability.
🌐 Open access:
Human challenge studies and norovirus dose-response
6. Atmar RL, et al. 2014. Determination of the 50% human infectious dose for Norwalk virus. The Journal of Infectious Diseases.
→ A landmark controlled human challenge study in which volunteers received different doses of Norwalk virus. Researchers estimated the dose associated with infection in 50% of susceptible participants, finding that estimates depended on which participants were included. The study also illustrates the distinction between RT-PCR units, genomic equivalents, and infectious virus particles and why infection does not necessarily mean symptomatic illness.
🌐 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC3952671/
7. Teunis PFM, et al. 2008. Norwalk virus: How infectious is it? Journal of Medical Virology.
→ An influential dose-response modeling study using human norovirus challenge data. The researchers examined viral infectivity, aggregation, and variation in susceptibility, illustrating how mathematical assumptions influence estimates of infection probability. This paper provides an important foundation for the episode's explanation of probabilistic infection and why a single infectious unit may theoretically initiate infection without establishing a universal minimum dose.
🔒Subscription required: https://onlinelibrary.wiley.com/doi/10.1002/jmv.21237
8. Ge Y, et al. 2023. Effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms. Emerging Infectious Diseases.
→ A secondary analysis of human norovirus challenge data investigating whether the initial inoculum influences viral shedding, symptom onset, and illness severity. Higher doses were associated with earlier symptom onset and faster viral shedding, while findings concerning severity and total shedding were less conclusive. This study supports an important distinction in the episode: increasing infectious dose can increase infection probability without necessarily producing more severe disease.
🌐 Open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC10310361/
Influenza and the importance of exposure route
9. Alford RH, et al. 1966. Human influenza resulting from aerosol inhalation. Proceedings of the Society for Experimental Biology and Medicine.
→ A landmark human influenza challenge experiment demonstrating that infection could occur following exposure to relatively small quantities of aerosolized influenza virus. The study illustrates why exposure route matters when interpreting infectious-dose estimates, and why results from controlled aerosol experiments cannot automatically be applied to every influenza exposure.
🌐 OPen Access - PDF available at link: https://pubmed.ncbi.nlm.nih.gov/5918954/
10. Teunis PFM, Brienen N, Kretzschmar MEE. 2010. High infectivity and pathogenicity of influenza A virus via aerosol and droplet transmission. Epidemics.
→ A dose-response modeling study synthesizing 12 human influenza challenge studies to investigate differences between aerosol inhalation and intranasal inoculation. The researchers estimated substantially greater infectivity through aerosol exposure under their model assumptions. This provides direct support for the episode's discussion of how exposure route influences infectious-dose estimates, while illustrating why results from different inoculation methods must be interpreted cautiously.
🌐 Open Access:
Research ethics and the history of human experimentation
11. Presidential Commission for the Study of Bioethical Issues. 2011. "Ethically Impossible": STD Research in Guatemala from 1946 to 1948.
→ An official historical investigation into U.S.-supported research in Guatemala involving deliberate exposure of vulnerable people to sexually transmitted infections without informed consent.
🌐 Free government report - PDF at link:
12. Centers for Disease Control and Prevention (CDC). About the Untreated Syphilis Study at Tuskegee.
→ A historical account of the U.S. Public Health Service study in which Black men with syphilis were deceived about the nature of the research and denied effective treatment.
🌐 Free online resource: https://www.cdc.gov/tuskegee/about/index.html
13. World Health Organization (WHO). 2021. WHO Guidance on the Ethical Conduct of Controlled Human Infection Studies.
→ International ethical guidance addressing studies in which consenting volunteers are deliberately exposed to infectious agents under controlled conditions. It explains the need for scientific justification, independent ethical review, informed consent, careful participant selection, and risk minimization.
🌐 Free WHO publication: https://www.who.int/publications/b/59194
Measles and population-level transmission
14. Guerra FM, et al. 2017. The basic reproduction number (R₀) of measles: A systematic review. The Lancet Infectious Diseases.
→ A systematic review examining estimates of the basic reproduction number for measles and the factors contributing to variation between populations and settings. It supports the episode's distinction between infectious dose, which concerns infection probability in an individual, and R₀, which describes transmission at the population level.
🔒 Subscription required:
Prevention and reducing exposure
15. Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH). Ventilation and respiratory infection prevention guidance.
→ Public-health and occupational-health guidance explaining how ventilation, air filtration, and respiratory protection can reduce exposure to infectious respiratory particles. These resources support the episode's discussion of layered prevention and the distinction between reducing exposure and guaranteeing that infection cannot occur.
🌐 Free online resource: https://www.cdc.gov/niosh/ventilation/about/index.html
16. Centers for Disease Control and Prevention (CDC). How to Prevent Norovirus.
→ Practical, evidence-based recommendations for preventing norovirus transmission, including handwashing with soap and water, food safety, and cleaning and disinfecting contaminated surfaces.
🌐 Free online resource: https://www.cdc.gov/norovirus/prevention/index.html
Comments